The receipt of a US patent for a new treatment method for Parkinson's disease is a significant positive development for Impel Pharmaceuticals. This could potentially lead to increased revenues in the future as the company can now exclusively sell this treatment in the US. This news is likely to increase investor confidence in the company, leading to a rise in its stock price in the short term.